Estrella Immunopharma (NASDAQ:ESLA) versus Applied Therapeutics (NASDAQ:APLT) Financial Contrast

Applied Therapeutics (NASDAQ:APLT) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Applied Therapeutics and Estrella Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Estrella Immunopharma	N/A	N/A	-397.36%

Volatility & Risk

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Earnings & Valuation

This table compares Applied Therapeutics and Estrella Immunopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1.00 million	15.86	-$105.62 million	($0.10)	-1.03
Estrella Immunopharma	N/A	N/A	-$13.06 million	($0.34)	-2.47

Estrella Immunopharma has lower revenue, but higher earnings than Applied Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Applied Therapeutics and Estrella Immunopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1	2	0	0	1.67
Estrella Immunopharma	1	0	1	0	2.00

Applied Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 852.38%. Given Applied Therapeutics’ higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Estrella Immunopharma.

Summary

Applied Therapeutics beats Estrella Immunopharma on 7 of the 12 factors compared between the two stocks.

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Estrella Immunopharma

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.